Blog Viewer

Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity

By Currents Editor posted 07-30-2021 11:37

  

Critical Care Medicine (07/02/21) DOI: 10.1097/CCM.0000000000005149

Gutierrez, Cristina; Brown, Anne Rain T.; May, Heather P.; et al.

https://journals.lww.com/ccmjournal/Abstract/9000/Critically_Ill_Patients_Treated_for_Chimeric.95168.aspx 

In a new study, U.S. researchers report a multicenter cohort of patients who required ICU admission due to cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor (CAR) T-cell therapy. The retrospective cohort study included 105 adult patients treated with axicabtagene ciloleucel who experienced CRS or immune effector cell-associated neurotoxicity syndrome between November 2017 and May 2019. When admitted to the ICU, 66.7% of the patients had grade 3–4 toxicities, including 15.2% with grade 3–4 CRS and 64% with grade 3–4 immune effector cell-associated neurotoxicity syndrome. While in the ICU, CRS was observed in 77.1% of patients and immune effector cell-associated neurotoxicity syndrome was seen in 84.8% of patients. A total of 61.9% of the patients had both conditions. Additionally, while 79% of patients developed grade 3 or higher toxicities while in the ICU, vasopressors, mechanical ventilation, and dialysis were not required often. Conditions including Immune Effector Cell-Associated Encephalopathy score less than 3, seizures, status epilepticus, motor deficits, and cerebral edema were more common. Overall, 8.6% of the patients died while in ICU; however, only three deaths were related to CRS or immune effector cell-associated neurotoxicity syndrome. The median overall length of survival was 10.4 months. The researchers note that neither toxicity grade nor organ support affected overall survival, while higher cumulative doses of corticosteroids were linked with reduced overall survival and progression-free survival.

#LiteratureWatch

FURTHER READING
By Shweta Goswami, MD; Eunice J Lee, MD; Rachael Scott, PharmD, BCCCP; Naomi Niznick, MD; Sasha Yakhkind, MD; Pouya Ameli, MD, MS; and Marc Babi, MD The role of practice management education—an umbrella term to describe salary negotiation, billing and coding, law and malpractice, and so on—has been ...
By: NCS Research Operations Subcommittee: Caitlin Brown PharmD, Michelle Schober MD, Shraddha Mainali MD, Cassia Righy MD, Minjee Kim MD, Tom Lawson CNP, Jennifer Kim MD, PhD, Ruchi Jha MD Can you tell me a little about yourself and how you got involved in the Neurocritical Care Society?   I ...
Yasser B. Abulhasan, MBChB, FRCPC, FNCS, Chairman, Neurocritical Care-MENA Chapter of IPACCMS It was a great pleasure organizing the 2 nd Neurocritical Care Regional Meeting in the Middle East and Africa in conjunction with the 17 th edition of the Emirates Critical Care Conference (ECCC). The meeting ...